White Paper on Measurement of Quality Outcomes  by Jones, Roy B. et al.
A
W
I
C
d
o
q
q
e
T
c
a
m
d
r
n
o
d
i
r
m
g
p
t
r
S
Q
s
f
A
T
ﬁ
s
T
s
i
a
i
Biology of Blood and Marrow Transplantation 12:594-597 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1205-0012$32.00/0
doi:10.1016/j.bbmt.2006.04.001
5SBMT COMMITTEE REPORT
hite Paper on Measurement of Quality OutcomesCommittee on Hematopoietic Cell Therapy Quality Outcomes: Roy B. Jones, MD, PhD (chair),
Claudio Anasetti, MD, Peggy Appel, MHA, John DiPersio, MD, PhD, Helen Heslop, MD,
Fred Lemaistre, MD, Sam Silver, MD, PhD, Janet Sirilla, RN, MSN, Patrick Stiff, MD
o
a
a
d
M
e
m
t
1
2
3
4
5
6
a
g
a
bNTRODUCTION
At the Transplant Center Medical Director’s
onference conducted during the 2005 BMT Tan-
em Meetings, presentations and discussions focused
n the feasibility and desirability of evaluating the
uality of center-speciﬁc transplant outcomes. Subse-
uent to that meeting the ASBMT Board of Directors
stablished a Committee on Hematopoietic Cell
herapy Quality Outcomes to further explore this
oncept. During the past year, the Committee evalu-
ted this proposal and submitted a series of recom-
endations to the ASBMT Board of Directors as
escribed below. The ASBMT Board approved the
ecommendations of the Committee at the 2006 An-
ual Meeting in Honolulu. The pivotal recommendation
f this Committee and the Board is that ASBMT should
evelop a process for center-speciﬁc quality outcomes report-
ng.
Because there are substantial implications to this
ecommendation, the Board requested that the Com-
ittee develop a white paper outlining the rationale,
eneral operational plan, and implications of this pro-
osal, recognizing that broad support from the hema-
opoietic cell transplant (HCT) community will be
equired.
UMMARY OF THE COMMITTEE RECOMMENDATIONS
The Committee on Hematopoietic Cell Therapy
uality Outcomes unanimously recommended that a
ystem to describe the quality of clinical outcomes
rom individual HCT centers be developed, and that
SBMT should vigorously involve itself in this effort.
he value of involving experts in developing and de-
ning quality measures in HCT is exempliﬁed by the
uccess of Foundation for the Accreditation of Cell
herapy (FACT). As the professional society for phy-
icians and others engaged in HCT, ASBMT embod-
es the expertise required to develop meaningful and
ppropriate outcomes measures that best serve the
nterests of our patients and our programs. The obvi-
94us risk of inaction at this time is to accept criteria
pplied by others with the associated potential haz-
rds.
The solid organ transplant community has already
eveloped a nationwide system for quality reporting.
any elements of that system can serve to guide our
fforts. The Committee believes the following ele-
ents are required for an outcomes reporting system
o be valid and valuable:
) Centers must provide comprehensive data report-
ing of outcomes for patients treated. Reporting only
narrowly deﬁned cohorts of patients cannot reﬂect over-
all center quality. At the same time the additional effort
inherent in using the system should be minimized.
) A centralized authority should receive and analyze
individual patient data from each center. Governance
for this authority should be deﬁned in such a way to
assure validity of analysis and reporting.
) A data set of sufﬁcient breadth to describe each pa-
tient’s demographics, disease state, treatment, comor-
bidities, outcome, and other factors relevant to quality
assessment should be identiﬁed.
) A system for electronic data transfer from centers to
the centralized authority should be developed.
) This system should be designed to provide incentives
inherent to the reporting design.
) Center participation in the design and implementation
of this system should be encouraged.
To ensure that outcomes data are accurate, useful,
nd fairly applied, several important principles must
uide this effort:
) Recognition of diversity of individual programs.
The plan for outcomes reporting should recognize,
for example, that larger centers treating high-risk
patients with research objectives and smaller cen-
ters treating limited numbers of patients on stan-
dard protocols are both valuable to the health care
enterprise. A meaningful quality analysis must ac-
count, without penalty, for this diversity.
) Quality assurance and improvement. Data de-
rived from outcomes reporting must be accessible
for program improvement. It should also enhance
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Brather than obfuscate the ability of patients and
payers to obtain appropriate transplant care. For
these reasons as well as those previously men-
tioned, the individuals most familiar with HCT are
best positioned to establish standards for outcomes.
) Minimal burden for data collection. Electronic
systems should be designed to easily interface with
pre-existing systems in centers with established in-
formatics efforts, but also to enhance and simplify
data collection and analysis in centers with fewer
informatics resources. Already-existing reporting
systems should be leveraged to minimize the re-
porting burden. These are critical issues to control
cost as well as to assure data accuracy and integrity.
ATIONALE
Development of an equitable and valid HCT out-
omes system will be complex and require consider-
ble time and effort. It seems clear, however, that the
emand from centers, patients, and payers for such a
ystem is high and will not dissipate. There is a sig-
iﬁcant concern that present data collection and anal-
sis methods used by the payer community are both
nadequate and inaccurate. Successful development of
scientiﬁcally based outcomes reporting system will
ot only improve center quality, but also will provide
n invaluable resource for research. It is clear that the
CT community already has or can identify the sci-
ntiﬁc resources to develop this system.
In addition to payer and patient demand for qual-
ty outcome data, new federal statutes and regulations
ave broadly expanded the authority of agencies to
ollect this information. The recently passed Stem
ell Therapeutic and Research Act (H.R. 2520) au-
horizes the Health Resources and Services Adminis-
ration (HRSA) to collect outcome data from all pa-
ients receiving allogeneic transplants in the United
tates. The agency has indicated its intent to do this
ut is encouraging collaboration in the design and
xecution of the collection system. HRSA intends to
olicit applications for a coordinating center to direct
his effort before Oct. 1, 2006.
The Committee strongly endorses the view that
SBMT participation in this plan is desirable to op-
imize the data collection and analysis process.
TATUS
) Comprehensive Data Reporting
The Committee has concluded that only compre-
ensive data reporting from all participating centers
an serve to adequately assess patient outcome quality.
his has also been the conclusion of the solid organ
ransplant community, which requires that 95% of all
atients at individual centers be reported for partici- t
B&MTation in Medicare (HRSA). We obtained statistical
onsultations that also conﬁrmed this opinion. The
otential distortions of cohort reporting are evident.
arge research centers could report only “standard
isk” patients treated on state of the art programs to
aximize the appearance of quality. Community-
ased centers might report only low-risk procedures
or the same reason. Neither would adequately reﬂect
verall center performance, nor support the value of
he speciﬁc missions of each type of center.
The particular burden of equity and accuracy of
eporting deserves emphasis here. Academically based
esearch centers are concerned that treatment of high-
isk patients in novel research studies will bias toward
oorer outcomes and not recognize the value of re-
earch in the creation of newer approaches to ex-
anded patient cohorts in the future. Smaller commu-
ity-based programs worry that a limited number of
oor outcomes in a small treatment sample might
nfairly reﬂect on the program’s quality. The require-
ent for comprehensive data reporting can assist in
ddressing these and similar issues. In both of the
xamples described above, the comprehensive report-
ng of all patients with covariate data to allow appro-
riate risk adjustment coupled with the analysis of this
ata over time will afford meaningful and fairly ap-
lied outcomes analysis.
Work to Date: Statistical consultation has been
btained to conﬁrm the necessity for comprehensive
ata reporting. The Committee consulted with ex-
erts in the design of solid organ transplant outcome
nalyses. The Web site www.ustransplant.org de-
cribes their approach to this problem. A registry was
stablished—the Scientiﬁc Registry of Transplant Re-
ipients (SRTR)—which is administered by the Uni-
ersity Renal Research and Education Association
URREA) at the University of Michigan. Reporting
ules and methods were established as collaboration
etween Medicare (which funds many solid organ
ransplants) and transplant organizations. Center-spe-
iﬁc outcome data are available to the public through
his Web site.
Committee members have met with representa-
ives of the commercial payer community during a
nited Network for Organ Sharing (UNOS) confer-
nce and were given broad conceptual support for
ore comprehensive outcomes reporting. The costs
f this reporting and analysis are ongoing subjects of
iscussion. The feasibility of establishing outcomes
eporting for HCT is clearly linked to the ability to
chieve meaningful data reporting within an accept-
ble cost range to the transplant program.
) Centralized Reporting/Analysis Authority
A central reporting/analysis authority similar to
he SRTR will be required for this effort. Expertise in
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5entralized HCT data analysis and reporting is avail-
ble through both CIBMTR and NMDP. CIBMTR
as developed a Web site (http://www.cibmtr.org)
ool for individual patient manual data entry and re-
orting. In the case of the Registry, a cultural change
rom the present voluntary reporting system would be
equired for it to assume this role. Discussions with
IBMTR and NMDP staff have been approved in
rinciple by the ASBMT Board of Directors. Other
stablished entities such as URREA could serve this
unction.
Data analysis must be accurate and equitable. The
ommittee recommends that methods development
ollow the general outlines used by the solid organ
ommunity. In this construct, sufﬁcient individual pa-
ient outcome data from centers is acquired to de-
cribe a desired outcome (most commonly survival)
or the national population. A typical Kaplan-Meier
urve with conﬁdence intervals is used. For individual
enters, patient, disease and treatment covariates are
sed to risk-adjust the center population and describe
center-speciﬁc expected Kaplan-Meier survival out-
ome. The actual Kaplan-Meier outcome for the cen-
er is then compared to that expected, using consensus
tandards to establish boundaries around the expected
utcome. Repeated actual outcomes outside these
oundaries can trigger a series of more intense out-
ome reviews, site visits and so forth. Serial evaluation
f national data using established covariates and
eighting are used to update the model validity, and
an trigger new covariate adjustment methods if the
xpected national outcomes deviate importantly from
hat observed.
Identiﬁcation of an appropriate central authority
nd funding it are critical but practical requirements.
t is possible that the entity selected by HRSA to
eceive and analyze allotransplant reports might be
ell positioned to perform this function.
Work to Date: Committee representatives have
et with both CIBMTR and URREA who have
xpressed an interest in serving as the central au-
hority for this effort. HRSA has been supportive of
his effort because it coincides with the agency’s
andate to collect allotransplant outcome data. Sta-
istical consultants have endorsed the conceptual
esign. As stated by one: “Adequate data collection
nd not analysis is always the primary barrier to this
ype of large project. Given sufﬁcient time, re-
ources, expert involvement and personnel, a fair
nd comprehensive analysis can always be done.
ithout comprehensive data acquisition at the cen-
ral authority, none of this is possible.”
) Data Set
Using individual data to construct an expected
aplan-Meier outcome for an individual center re- l
96uires at least two elements: a) model development
hich fairly and equitably uses covariates to adjust for
ndividual center and patient characteristics, and b)
eporting sufﬁcient covariate data on each patient to
llow model development and adjustment. Ideally in-
ividual patient data sets must be both comprehensive
nd minimally burdensome to submit. Identiﬁcation
f this data set is a critical step in this effort. Given the
ecessity of electronic data submission, changes in the
ata set will require extensive alterations at both the
atabase and data transmission levels and must be
mportant to be accommodated. We believe it is crit-
cal to widely consult about the content of this data set
nd conduct a pilot analysis of its use before nation-
ide implementation of any outcomes analysis system.
Committee representatives have met with the
IBMTR, NMDP and representatives of the Emmes
orporation who are collaborating in the construction
f a set of Common Data Elements (CDEs) which will
orm the future basis for transplant reporting by the
CI, NHLBI, CIBMTR and NMDP. Use of the
DEs to store data in individual transplant center,
egistry or coordinating center databases should
reatly facilitate data storage, reporting and analysis.
The Committee identiﬁed comorbidity conditions
s a major area of deﬁciency in most current data
ollection schemes. Comorbidity data becomes critical
or outcomes reporting as older and more compro-
ised patients are transplanted.
Work to Date: A subcommittee was established to
egin identiﬁcation of important data elements to be
ollected in the data set. Members have developed a
reliminary data set which was discussed at the 2006
SBMT Annual Meeting. Describing this data using
DEs should be completed by the third quarter of
006.
) Electronic Data Transfer
Development of methods for electronic data
ransfer to the central analysis/reporting authority is
ssential for this project to succeed. This system must
aximally utilize existing databases at individual cen-
ers, nurture the development of standardized elec-
ronic data storage at centers where none exists, and
acilitate the upgrading of data storage at centers using
utdated or inadequate technologies. At the same
ime, it must provide a portal for manual data entry at
enters unable to use ﬁle transfer methods.
To accomplish this task, an assessment of computer
xpertise and data storage methods employed at trans-
lant centers was required. For centers with extensive
atabase resources, facile ﬁle transfer will likely be the
referred data communication method. For other cen-
ers, an internet portal similar to that in use by the solid
rgan transplant community and CIBMTR which al-
ows manual data transfer may be preferred.
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BWork to date: To assess the level of computer and
atabase expertise at the various centers, a question-
aire was developed and submitted to all program
irectors through the ASBMT Web site. Twenty-ﬁve
ercent of centers responded and indicated a relatively
igh level of computer expertise at the responding
ites. Speciﬁcally, more than one-half of the respond-
ng centers had access to a computer database admin-
strator and stored data electronically at their center.
ONCLUSIONS
Extensive center-speciﬁc quality outcomes analy-
is will be required in the future by health insurers,
ederal agencies and patients. The Committee on He-
atopoietic Cell Therapy Quality Outcomes and the
SBMT Board encourage transplant center participa-
ion in the design of the required systems. These
ystems are essential to maximize validity, equity and
esearch value of the collected data while minimizing
ost. The primary beneﬁt of this activity is to assure
ndividual centers, patients and the payers that BMT
utcomes meet validated national performance stan- T
B&MTards. The existing FACT mechanism for center ac-
reditation might represent an ideal vehicle to encour-
ge the changes required to insure quality, as clinical
utcomes are already examined in their accreditation
rocess. The FACT process will also maximize peer
nvolvement in this process.
In addition to the quality assurance/improvement
eneﬁts of this effort, BMT research should be en-
anced. The data contained in the central reporting
uthority will be a rich source for publication. Perhaps
ore importantly, however, the data submissions
rom each center will provide a ﬁrm basis for stan-
ardization and organization of data in centers where
uch efforts have not previously been undertaken. The
bility of the central authority to provide each center
ith its own relational database version will enhance
he research output of centers and of ad hoc consortia
rought together to answer focused research ques-
ions. In this way quality outcome analysis merges
ith research productivity to the beneﬁt of our ﬁeld.
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